Category: NASDAQ

For the past couple of years, the biotech industry has seen a massive boom as an increasing number of biotechnology companies raced to develop treatments and vaccines for the COVID-19 virus. Among investors, the biotechnology market remains a hot market showing signs of major growth long-term. In this article, we discuss some of the hottest Biotech stocks investors are looking at right now – Adaptive Biotechnologies Corporation NASDAQ: ADPT, Aldeyra Therapeutics, Inc. NASDAQ: ALDX and 

BIOTECH STOCK #1: ADPT

The commercial-stage biotechnology company, Adaptive Biotechnologies Corporation (NASDAQ: ADPT) is most known for its work to transform the genetics of the adaptive immune system into clinical products to diagnose and treat diseases.

The company has been on investors’ radar ever since it launched the second test in its growing T-Detect franchise – T-Detect Lyme. By leveraging the body’s unique T-cell response to disease-associated antigens, T-Detect Lyme enables patients and healthcare providers to detect and diagnose early Lyme disease.

An early diagnosis of Lyme disease enables treatment to stop its progression. But, today’s standard antibody tests could miss up to 75% of Lyme disease cases in the early phase of infection. 

In a recent clinical study of patients with early Lyme disease, the T-cell test proved more accurate with almost 99% specificity than other leading antibody tests. The test also showed over 1.5 times greater sensitivity than standard two-tiered testing (STTT) in numerous patients. Given that Lyme disease is the most common tick-borne illness with an average 476 thousand Americans diagnosed and treated every year, this test is a breakthrough that could bring a plethora of growth opportunities for ADPT moving forward.

Sharon Benzeno, Ph.D., chief commercial officer, immune medicine, Adaptive Biotechnologies seems bullish on the company’s future following the announcement: 

The addition of T-Detect Lyme will support scaling clinical operations to enable our growing T-Detect portfolio, including testing in autoimmune disorders with high unmet need”

Now trading at $8.73, ADPT has cooled off following its recent run-up which formed a new resistance at 9.21. The stock shows a support at 7.71 & 6.75. Accumulation has been on an upward trend but is recently declining. Similarly, the RSI was at 75 indicating the stock was overbought but has now cooled off near 57. Meanwhile, the MACD has shown a series of bullish crossover but is now on the verge of a bearish crossover.

These indicators collectively show the stock losing its momentum following the run-up. The decline in accumulation could resemble the increasing number of investors cashing out for profits supported by a decreasing RSI reflecting the sell-out. Given that ADPT shows strong support at 7.71 & 6.75, bullish investors could wait for the RSI to regulate before finding a good entry point on this promising stock.

BIOTECH STOCK #2: ALDX

Since its inception, Aldeyra Therapeutics, Inc. NASDAQ: ALDX has been developing innovative therapies specifically designed to treat immune-mediated diseases. The company has been gaining attention mostly because of its two lead products – reproxalap and ADX-629 – which target systems-based mediators of inflammation: RASP (reactive aldehyde species). Currently in its late-stage clinical trials, Reproxalap targets patients with dry eye disease & allergic conjunctivitis. 

As of recently, the company announced a new achievement in Phase 3 TRANQUILITY-2 clinical trial of reproxalap. According to the Schirmer test, a measure of ocular tear production and the dry eye disease objective sign most commonly utilized for drug approval – Reproxalap proved statistically superior to the vehicle for each of the two prespecified primary endpoints.

With this in mind, Jacob R. Lang, O.D., F.A.A.O. – a dry eye disease specialist for Associated Eye Care in St. Paul – commented that:

“Based on its rapid symptomatic control demonstrated across multiple clinical trials, reproxalap has the potential to be not only an important treatment option but a first-line therapy for dry eye disease.”

Looking to the future, Todd C. Brady – President and CEO – highlighted the great impact of this achievement:

For many of the more than 39 million U.S. adults who suffer from dry eye disease, we believe the need for a rapidly acting therapy with a novel mechanism of action is significant. We are confident in the potential of reproxalap to meet that need.”

Ending the trading week on a high note, ALDX is trading at $3.67 with support near 3.18 and 3.04. Its massive run-up earlier this month formed a new resistance at 4. The MACD is bullish but seems poised for a bearish crossover. Meanwhile, accumulation is on an uptrend and the RSI is at 78 – indicating the stock is overbought.

Considering these indicators, the stock could plummet to its support as the RSI cools off and investors cash out for profits. For this reason, bullish investors could wait for the indicators to regulate before finding a good entry point on this emerging biotech stock.

BIOTECH STOCK #3: ADTX

As a nation-leading advanced molecular diagnostics lab, Premier Medical Laboratory Services (PMLS) is fully certified by top laboratory accrediting organizations such as CLIA and COLA. Recently, the company announced it is adding AditxtScore to its growing menu of testing services.

AditxtScore allows patients to know the protection level they have from an immune response to the virus or vaccination. Given that a large segment of the population has already undergone vaccination for COVID-19, AditxtScoreä is well-positioned to provide information on immune status during the ongoing phase of the pandemic.

This could be crucial because while the virus continues to spread and the implications of the new variants are unknown, AditxtScoreä can be used to identify changes in immune response over time and contribute greatly to the continued understanding of responses to COVID-19 and its mutants.

ADTX is currently trading at $.1560 near its support of .1393. It also shows a resistance near .2496 and .3004. Accumulation has been trending downwards but is recently seeing a slight uptick. The MACD is bullish and the RSI is at 58.

The drop in accumulation could be the result of investors cashing out for profits following the run-up. However, the RSI continues to indicate the stock is slightly overbought. Investors bullish on the company’s latest announcement could find now a good entry point since the stock is trading near its support, or they could wait for the RSI to cool off to 50 before making an entry.

Unlike most industries, the inflation and the post-pandemic effect barely affected the biotechnology industry. In fact, many biotech companies thrived in those hard times. In this article, we will go over 3 of the best biotech stocks you can add to your portfolio, Kezar Life Sciences, Inc. (NASDAQ: KZR), Decibel Therapeutics (Nasdaq: DBTX) and Sutro Biopharma, Inc. (NASDAQ: STRO).

Viral Stocks video covering these Biotech Stocks and MORE!!! DO NOT Miss it!

#1 Best Biotech Stocks: KZR

Starting the day with over a 70% run up, Kezar Life Sciences, Inc. (NASDAQ: KZR) is the talk of the town today. The biotechnology company just announced positive results on an ongoing study for its lead product candidate which was the spark that ignited the KZR stock major increase. 

As a leading clinical-stage biotechnology company, Kezar focuses on discovering and developing new small molecule therapeutics for immune-mediated disease and cancer. The company operates in the United States, accordingly Kezar is trying to fill the gaps in the US therapeutics market. 

On 27 June, Kezar released the results of the mission phase 2 trial evaluating Zetomipzomib (KZR-616)  – KZR’s current lead product. The drug is planned to treat patients of lupus nephritis, a disease estimated to hit 1.5 million US citizens and at least five million people around the world. 

The results of the study show significant positive results, overall Zetomipzomib is shaping up to be an immunomodulatory, well-tolerated, and steroid-sparing drug. On that note, the company’s Chief Medical Officer – Noreen R. Henig, M.D. – said

Based on the strength of these results, we plan to continue developing Zetomipzomib for patients with lupus nephritis, as well as evaluate development opportunities for systemic lupus erythematosus.

Following the initial 71% run-up, KZR dropped a little however the stock is still trading much higher than it was yesterday with almost a 50% increase. Currently, KZR is trading at $8.35 with a newly formed resistance near 12.25 and primary support around 5.61 as well as secondary support at 4.36. 

Meanwhile accumulation is trending downwards and RSI is at 70 indicating that the stock is overbought. On the other hand, MACD is on a recent bullish crossover. Although some of the indicators are showing negative signs, after a major run that’s nothing to worry about. With that in mind, many investors are bullish that following another news on Zetomipzomib, KZR might go on a higher run-up and reach its 52-week high of $18.3.

Sign up for our free alerts to get the hottest NYSE, NASDAQ and Penny Stocks daily!

#2 Best Biotech Stocks: DBTX

Among the best biotech stocks today is Decibel Therapeutics (Nasdaq: DBTX). Like KZR, Decibel is a clinical-stage biotechnology company. However, Decibel works on discovering and developing treatments for restoring and improving hearing and balance. 

The biotech company recently announced the results of its Phase 1 clinical trial of DB-020. As a drug developed to protect cancer patients on cisplatin chemotherapy from ototoxicity that leads to permanent hearing loss, DB-020 will be the only treatment in the market available for ototoxicity. With no direct competitors, the potential of the drug is extremely promising, especially since it’s already showing positive results. 

The Phase 1 clinical trial included treating patients with DB-020 in one ear and a placebo in the other. The results of the trial revealed that around 88% of patients experienced ototoxicity in the ear that was treated with a placebo. Whereas, 87% of these patients were partially or completely protected from ototoxicity in their DB-020-treated ears.

These great results support the continuation of the clinical trials and soon enough the treatment will be ready for the public. Decibel’s management promises to update its shareholders at the upcoming medical conference. 

Currently, DBTX is trading at $2.73 with resistance around 2.88 and support near 2.23 as well as a secondary one at 1.86. 

Although MACD is on a bullish crossover, accumulation is on a downwards trend. Meanwhile, RSI is holding at 60 indicating that the stock might be slightly overbought at the moment. Upon the release of the treatment, the stock might witness another run-up, to break its resistance and trade at its YTD high of $9.75.

#3 Best Biotech Stocks: STRO

Lastly, Sutro Biopharma, Inc. (NASDAQ: STRO) made the list of the best biotech stocks today on account of its collaboration with a global pharmaceutical company that has operations in over 70 countries. Which resulted in a 23% increase in the stock’s value. 

Recently, Sutro Biopharma announced its entrance into a global strategic collaboration and license agreement with the Japanese company – Astellas Pharma. Under the terms of the agreement, both companies will work on developing new immunostimulatory antibody-drug conjugates – iADCs. 

The drug is planned to treat cold tumors and provide a reliable drug to patients who are not responding to the existing immunotherapies. With the expertise of Sutro and Astellas, the potential of this treatment is unlimited. 

The agreement states that STRO will obtain $90 million in cash to develop iADCs for 3 biological targets. Following that, the company may be eligible to receive up to $422.5 million for the next stages of development and commercialization of each product candidate. 

Additionally, Sutro has the option to contribute to the costs and profits of the product candidates in the US. However, if STRO exercises that option for one product candidate, then both companies will equally split the costs of development and commercialization of that product. Accordingly, the profits or losses of that product candidate will be equally shared among Sutro and Astellas.

Upon the announcement, STRO witnessed a 20.79% increase to be traded at $5.22. The stock has a newly formed resistance at 5.25, a primary support around 4.15 and a secondary stronger one near 3.38. 

The RSI stands at 72 indicating that the stock is currently overbought. Meanwhile, accumulation is on a downwards trend, but MACD is on a recent bullish crossover with no signs of another crossover in the near future. 

The biotech market is getting hotter by the minute, if you are not investing in biotechnology stocks these days then you are missing out on huge returns! Just this morning two biotech companies dominated the top stock gainers list. Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) and Catalyst Biosciences, Inc. (NASDAQ: CBIO) have always been exceptional companies yet today they are breaking new records and gaining well-deserved momentum. Resulting in major run ups for both stocks!

#1 Top Stock Gainers : ALNA

With almost a 190% increase, Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) has been making headlines this morning. This major run up was caused by the company announcing the termination of its agreement with B. Riley Securities, Inc. 

ALNA is a biotechnology company that works on discovering and developing enzyme therapeutics to treat patients in the US from kidney disorders as well as rare and severe metabolic disorders. Meanwhile, B.Riley is a financial services provider that focuses on fulfilling any enterprise’s financial need at all stages of the business life cycle.

Last December, the companies entered into at market issuance sales agreement (ATM agreement). Since then and till the 27th of June, B. Riley was able to issue and sell at-the-market offering shares of ALNA’s common stock with a par value $.001 per share.

On 28th of June Allena filed an 8-K with the SEC to announce the immediate termination of its ATM agreement with B.Riley. 

Investors are bullish on these news, given that such an event usually leads to a rapid increase in the stock’s value. You missed out on ALNA? Get our free alerts & find out the top stocks gainers before anyone else! 

Following the termination of the agreement, the stock witnessed a major 186% run up to be currently traded at $.3172. The stock has a newly formed resistance at .3932 with a strong support line near .1073. 

With any major increase in a stock’s value, the RSI always tends to also skyrocket. With that in mind the RSI of ALNA hit 91 in the beginning of the trading day, however at the moment it stands at 70 indicating that the stock is overbought. Meanwhile, the MACD is on a recent bullish crossover and showing no signs of another crossover anytime soon. On the other hand, accumulation has been trending downwards. 

The run-up might not last for long, however, the stock has great potential moving forward so even if it dipped for a while, there’s a huge possibility that it would regain its momentum and trade at new highs. Our 100% free alerts will make sure you don’t miss the next run-up.

#2 Top Stock Gainers: CBIO

Secondly, among the top stock gainers, today is Catalyst Biosciences, Inc. (NASDAQ: CBIO) with over a 15% increase in stock value. The biotech company is on investors’ radar today as it announced its intent to distribute cash to its shareholders.

As a biotechnology company, CBIO works on developing and commercializing protease therapeutics. In order to fulfill unmet medical needs of complement and coagulation systems disorders.

On June 29, the biotech company’s board of directors reported that they are planning on distributing cash to their stockholders through one or more payments as soon as practicable. Currently, CBIO expects that the total cash amount to be distributed could be up to $65 million.

On that note the CEO of the company –  Nassim Usman, Ph.D. – stated that 

This follows our recently completed sale of a portion of our product portfolio for up to $60 million in cash, $55 million upfront and $5 million in a 12-month hold-back, after a thorough and competitive process with the assistance of independent financial and legal advisors.

He also went on to add that the company has managed to aggressively cut costs through various routes such as reducing headcount, terminating R&D activities, and monetizing lab equipment. 

The initial distribution is expected to be after the evolution of the potential liability and expenses associated with the ongoing Delaware Court of Chancery stockholder litigation and the annual stockholders meeting initiated by a CBIO stockholder. 

It is also worth noting that the company intends to distribute all the available cash to its stockholders after fulfilling all its obligations and contingent liabilities. 

Following its major run-up, CBIO stock is currently trading at $1.72 with resistance at 1.8 and primary support around 1.3 as well as a secondary one near 1.09. 

Meanwhile, RSI stands at 62 indicating that the stock might be on its way to being overbought but at the moment that’s not a bad sign. Although MACD is on a recent bullish crossover, accumulation has been going steady with no real change in the charts. But no change is a good sign when it comes to the stock market. Check out our alerts to learn which stocks are trending upwards in real time!

As the industry recovers, biotech stocks like Humanigen, Inc. (NASDAQ: HGEN), Oramed Pharmaceuticals (NASDAQ: ORMP) and MyMD Pharmaceuticals, Inc. (NASDAQ: MYMD) are quickly garnering much-deserved attention from investors. In this article, we dive into all the reasons why we’re watching these stocks in the coming days as well as their upcoming catalysts. Stay up to date with the BEST and CHEAPEST biotech stocks to buy here!

Promising Biotech stocks #1: HGEN

Humanigen, Inc. (NASDAQ: HGEN) – a late-stage clinical biopharma company – is most known for its work to prevent & treat a life-threatening systemic immune hyper-response, associated with COVID-19, called: cytokine storm. For years now, the company has worked on developing Lenzilumab – a proprietary Humaneered first-in-class monoclonal antibody that neutralizes GM-CSF – a cytokine of critical importance in the hyperinflammatory cascade – cytokine storm.

On July 7th, the company announced a peer-reviewed publication in Thorax– one of the world’s leading respiratory medicine journals and the official journal of the British Thoracic Society. The report supported Early Treatment of Hospitalized COVID-19 Patients with Lenzilumab Guided by C-Reactive Proteinsaw and highlighted a 62% reduction in the relative risk of progression to mechanical ventilation or death.

Commenting on that, Dale Chappell, M.D. – HGEN’s Chief Scientific Officer – said that: “these data demonstrate the importance of selecting the right treatment for the right patient at the right time”. As of now, 90% of LIVE-AIR patients treated with Lenzilumab in addition to standard of care are more likely to survive without mechanical ventilation – compared to only 79% treated with placebo and standard of care.

Dr. Cameron Durrant – Chairman & CEO – is bullish on this progress saying:

We believe data from our LIVE-AIR study provides a compelling argument for utilizing CRP as a biomarker to identify hospitalized patients for whom lenzilumab may provide the greatest benefit and we look forward to results of the NIH’s ACTIV-5/BET-B study of lenzilumab, which is designed to confirm this approach”.

Following its run-up, HGEN is now trading at $3 with a new resistance at 3.2 along with support at 2.09 and 1.84. Accumulation has been fluctuating but is recently seeing an uptick, meanwhile, the MACD is bullish but seems poised for another crossover soon. On a similar trend, the RSI is at 76 – indicating the stock is currently overbought.

As more results resurface, HGEN could see another run-up to break its resistance sooner than expected. However, given that the stock is currently overbought, it is likely that HGEN could retest its support before seeing an increase again. For this reason, bullish investors could wait for a pullback before securing a position on one of the most promising biotech stocks this week.

Promising Biotech stocks #2: ORMP

In its recent shareholder letter, clinical-stage biotech Oramed Pharmaceuticals (NASDAQ: ORMP) announced several updates regarding the company and its subsidiary; Oravax Medical. Most importantly, the company reported a solid financial stance and robust balance sheet with $169 million in cash and investments.

With this in mind, the company is well-positioned financially and clinically and has multiple important milestones expected to play out in the upcoming quarters. As a matter of fact, CEO Nadav Kidron believes that:

This position gives us sufficient runway to complete our pivotal oral insulin (ORMD-0801) Phase 3 trials and advance us towards potential FDA approval.”

Speaking of which, the shareholder letter also mentioned that as of Q1 2023, the company plans to achieve one of its most significant milestones. Under a U.S. FDA protocol, ORMP plans to report top-line efficacy data in the world’s first-ever pivotal Phase 3 oral insulin trial for the treatment of type 2 diabetes. As of now, the compnay has already enrolled 710 participants – greatly surpassing the number of planned participants in the first of its two oral insulin trials ORA-D-013-1.

The release of this oral type 2 diabetes therapy could be an extremely lucrative opportunity for ORMP. Investors are quickly realizing the untapped potential of this company. This is evident as ORMP has seen a huge uptick in volume – with over 14.5 million shares being traded at the time of this writing. This run-up is likely to continue as more of its catalysts play out over the next six months.

Closing the trading week on a high note, ORMP is now trading at $8.21 near its resistance of 8.22. With support at 4.45 and 4.16, it seems investors are quickly realizing the untapped potential of this company. Accumulation has been climbing steadily and despite its slight downfall, it has recently seen an uptick. Similarly, the MACD is bullish to the upside with no signs of an incoming crossover and the RSI is at 80 – indicating ORMP is extremely overbought at the moment.

If the company announces FDA- approval of its drugs, ORMP could be set for another run-up soon to break its resistance – making now a good entry point for bullish biotech investors. However, given that the stock is currently overbought, it is likely for it to calm down before heading on another run. This is why investors could secure a starter position now and average up on their investment from there.

Promising Biotech stocks #3: MYMD

As a clinical-stage pharmaceutical company, MyMD Pharmaceuticals, Inc. (NASDAQ: MYMD) has been focused on developing 2 novel therapeutic platforms that treat causes of disease instead of only addressing symptoms. The company is most known for its commitment to extending a healthy lifespan.

The company’s first platform – MYMD-1 – is a drug platform being developed to delay aging, increase longevity, and treat autoimmune diseases. Meanwhile, its second drug platform – Supera-CBD – is being developed to treat chronic pain, addiction, and epilepsy.

Commenting on the progress, Chris Chapman, M.D. – President, Director, and Chief Medical Officer- said:

With all trial sites now enrolling patients, we expect the pace of enrollment to speed up over the next several months. As we continue to advance our trial, we currently expect efficacy data in the second half of 2022. This trial remains our number one priority in our product development strategy.”

Given that MYMD has not identified any other FDA-approved drugs for treating aging disorders and extending the healthy lifespan of humans – a market that’s expected to be valued at around $600 billion by 2025 – the company could be set to gain immensely if it dominates this extremely lucrative sector.

Let’s take a look at where the stock’s at now….

Following its recent run-up, MYMD is currently trading at $4.23 with support at 2.2 and 2.09. Accumulation has been on an uptrend but is recently fluctuating and could drop in the coming days as investors cash out for-profits after the massive increase in the PPS. Meanwhile, the MACD is bullish with no signs of an incoming crossover and the RSI is holding at 80 – indicating MYMD is currently overbought and affirming investors’ bullish sentiment.

BOTTOM LINE

With the industry rebounding from a rough nine-month period, biotech stocks have been a hot topic these past few weeks. This is why aggressive investors are increasingly on the lookout for the best biotechs to invest in. Get alerts on the best entry points for promising biotech stocks and make major returns INSTANTLY!

As always, good luck to all (except the shorts)!

Emerging biotechnologies are once again catching investors’ attention as more and more monkeypox cases are reported. In fact, earlier this week, WHO announced a global health emergency regarding the rapid increase in the Monkeypox spread. Taking into consideration the rising cases and awareness of the disease, it is highly likely that government funds will start to flow into companies with approved vaccines & manufacturing capacity.

In this article, we look at GeoVax Labs, Inc. (NASDAQ: GOVX), SIGA Technologies, Inc. (NASDAQ: SIGA), and Aethlon Medical, Inc. (NASDAQ: AEMD) and all the reasons why they are among the top Monkeypox stocks to play ahead of a potential pandemic.

Monkeypox Stocks To Buy #1: GOVX

GeoVax Labs, Inc. (NASDAQ: GOVX) is a biotechnology company focused on developing human vaccines & immunotherapies against infectious diseases and cancer. Its now flagship product – MVA-VLP-SUDV, combines the advantages of the immunogenicity of a live attenuated vaccine vector with the authentic conformation of virus-like particles (VLPs). It also has ideal vaccine properties that will support use in the general population.

In light of this advanced development, GOVX Chief Scientific Officer – Mark J. Newman – is bullish saying:

“The MVA-VLP platform allows for the design of vaccines to present the immune system with multiple viral proteins in the conformation that mimics the actual virus. The resulting immune responses are broadly functional, involving both the antibody and T-cell effector function, resulting in optimal levels of efficacy, even with a single dose.

On July 28th, the company announced the publication of a peer-reviewed animal efficacy study of its modified vaccine Ankara (MVA) vectored vaccine against Sudan ebolavirus (SUDV). CEO David Dodd, believes this publication “further validates the broad utility and benefit of the GOVX’s MVA-VLP approach towards providing single-dose, highly efficacious vaccines against major infectious health challenges worldwide.”

The company has already major financial and production progress in the previous quarter and has assured investors of upcoming updates. Many are bullish any updates could push GOVX beyond its current resistance point very soon….

Currently, GOVX is trading at $1.98 with a near resistance at 2.35. The stocks shows an immediate support at 1.79 and another at .63. Accumulation has been steady for the past couple of weeks as the stock traded near its secondary support point. However, it has recently fluctuated and is now on a downtrend. MACD is bearish but seems poised for another crossover soon. Meanwhile, the RSI is on a downtrend and is now holding at 57 – indicating the stock is relatively stable to trade.

Monkeypox Stocks To Buy #2: SIGA

As a commercial-stage pharma, SIGA Technologies, Inc. (NASDAQ: SIGA) is focused on the health security market. Its lead product; TPOXX – an orally administered and IV formulation antiviral drug – is developed for the treatment of human smallpox disease caused by the variola virus. Approved by the FDA for the oral and IV formulation, TPOXX showed efficacy across all orthodox viruses as it works by blocking the virus from exiting infected cells.

In light of this progress, the US government has been stockpiling the drug since 2013, and in 2020, the company signed a $629 million 5-year contract and assured investors it will continue scaling up the production of TPOXX to meet the increasing demand and control the spread of monkeypox.

With this in mind, SIGA recently announced its plans to host a conference call on August 4th to update investors on its progress so far. Participating in the call will be CEO Dr. Phil Gomez, CFO Daniel Luckshire, and Chief Scientific Officer Dennis Hruby. Investors are bullish on the upcoming update given the company’s continous efforts to capitalize on the spread of monkeypox.

Since we alerted SIGA, the stock broke its previous resistance and showed MASSIVE growth! Currently trading at its newly formed resistance of $22.4, SIGA is on a run-up and shows no signs of stopping. The stock has strong support at 14.79 and 13.73. Accumulation has been on a steady run-up and shows no sign of a reversal. Similarly, the MACD is bullish and the the RSI is at 81 and trending upwards – indicating SIGA is now extrremely overbought.

Investors are bullish on the company’s progress in the past couple of months and are expecting promising updates & milestones regarding a monkeypox vaccine very soon. In anticipation of the company’s upcoming update call, SIGA is seeing new highs and continues to be one of the best monkeypox stocks to invest in. If you missed SIGA’s run? Sign up here & never miss another hot stock!

Monkeypox Stocks To Buy #3: AEMD

As a medical therapeutic company, Aethlon Medical, Inc. (NASDAQ: AEMD) is focused on developing products to diagnose & treat cancer and life threatening infectious diseases. The company hit multiple milestones this month. As of July 11th, AEMD announced DA approval of an amendment to the protocol of its ongoing clinical trial investigating the Aethlon Hemopurifier for patients with severe COVID-19.

More recently, the company announced the publication of a peer-reviewed journal article in PLOS ONE – another major milestone for AEMD. The article; “Removal of Clinically Relevant SARS-CoV-2 Variants by An Affinity Resin Containing Galanthus nivalis Agglutinin,” has data revealing that the proprietary GNA affinity resin of the Aethlon Hemopurifier efficiently captures 7 clinically relevant variants of the COVID-19 virus. With a viral capture efficiency ranging between 53% and 89% for the variants tested, AEMD’s Aethlon Hemopurifier has proven an effective and trusted treatment method.

Given the company’s ongoing efforts to diagnose & treat life threatning diseases, investors are watching AEMD closely as the Monkeypox spread continues to dominate many parts of the world.

Now trading at $1.08, AEMD has an immediate resistance near 1.09 and another at 1.2. The stock shows a near support at 1.05 and another at 1. Accumulation is heavily fluctuating and is now trending downwards. Similarly, the RSI is regulating and is now holding at 48. The MACD is bearish but seems poised for a reversal soon.